Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Patient-profiled treatment responses in a large hypertension trial: a posthoc analysis of the INSIGHT study.

Journal of hypertension·2026
Same author

Resistant Hypertension Is Not Essential: It Is Primarily Aldosteronism.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

EndoCompass Project: Research Roadmap for Adrenal and Cardiovascular Endocrinology.

Hormone research in paediatrics·2025
Same author

Adrenal Aldosterone Synthase Expression Imaging in Primary Aldosteronism.

The New England journal of medicine·2025
Same author

Voxel-Level Comparison of [<sup>18</sup>F]CETO and [<sup>11</sup>C]MTO for Molecular Imaging of Primary Aldosteronism.

Journal of nuclear medicine technology·2025
Same author

EndoCompass project: research roadmap for adrenal and cardiovascular endocrinology.

European journal of endocrinology·2025
Same journal

Eugene Braunwald, MD, 1929-2026.

Circulation·2026
Same journal

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026
Same journal

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same journal

Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association.

Circulation·2026
Same journal

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same journal

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Circulation·2026
查看所有相关文章

相关实验视频

Updated: May 11, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

阿里斯基伦 (Aliskiren) 是一种

Morris J Brown1

  • 1University of Cambridge, Cambridge, UK. m.j.brown@cai.cam.ac.uk

Circulation
|August 13, 2008
PubMed
概括
此摘要是机器生成的。

阿利斯基伦是一种口服宁抑制剂,在经批准的剂量中有效降低血压,副作用最小. 它显示出作为单一疗法或组合疗法的前景,特别是在抗性高血压.

更多相关视频

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

相关实验视频

Last Updated: May 11, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

科学领域:

  • 心血管药理学心血管药理学
  • 脏系统生理学 脏系统生理学

背景情况:

  • 高血压管理依赖于不同的药物类别.
  • 氨酸-氨酸-阿尔多斯特系统 (RAAS) 是血压的关键调节器.
  • 向宁提供了一种直接方法来抑制RAAS.

研究的目的:

  • 评估阿利斯基伦的疗效和安全性,阿利斯基伦是一种直接的宁抑制剂.
  • 评估阿利斯基伦在单一治疗和高血压联合治疗中的作用.
  • 探索在临床实践中利用aliskiren的最佳策略.

主要方法:

  • 评估降低血压的临床试验.
  • 在150 mg和300 mg的剂量反应评估.
  • 与其他抗高血压药物类别进行比较分析.
  • 安全性和耐受性评估与安慰剂对比.

主要成果:

  • 阿利斯基伦证明了与剂量相关的血压降低,与已知的抗高血压药物相比.
  • 副作用与安慰剂类似.
  • 在单一疗法和组合疗法中有效.
  • 当与尿剂结合使用时,观察到更大的益处,但双重宁阻断也显示出益处.

结论:

  • 阿利斯基伦是一种安全有效的口服抗高血压剂.
  • 它为患有失控或不耐受高血压的患者提供了一个有价值的选择.
  • 了解蛋白系统可以优化阿利斯基伦的治疗价值.
  • 需要进一步的结果研究来确定非血压心血管益处.